Clinical trials

Ongoing Protocols : click on the protocol for the inclusion-exclusioncriteria (update 1/08/2017)


Locally advanced

PET Boost
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC.

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.


LDK378-NIVOLUMAB (Novartis)
A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. 

INC280 (Capmatinib) (Novartis)
A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease.

A Phase 2 Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV
Non-Small Cell Lung Cancer.

LXH254, LTT462 (Novartis)
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. Temporarily on hold

CPDR001C2101 (Novartis)
Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patients.


Hippocampus Avoidance PCI vs PCI
Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial.

A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy.


NINTEDANIB (Boehringer Ingelheim)
Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma.


For further information regarding protocols or clinical trial unit description, please contact the datamanagers: